IRIS
RADAELLI, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 386
NA - Nord America 280
AS - Asia 52
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 724
Salva come PNG Salva come JPEG
Nazione #
SE - Svezia 296
US - Stati Uniti d'America 280
IT - Italia 30
CN - Cina 18
FI - Finlandia 13
IE - Irlanda 13
IR - Iran 12
NL - Olanda 10
GB - Regno Unito 9
IN - India 7
DE - Germania 6
JP - Giappone 6
TR - Turchia 6
CH - Svizzera 5
CO - Colombia 4
EU - Europa 2
SG - Singapore 2
FR - Francia 1
HK - Hong Kong 1
HU - Ungheria 1
NO - Norvegia 1
RU - Federazione Russa 1
Totale 724
Salva come PNG Salva come JPEG
Città #
Lawrence 72
Princeton 72
New York 23
Shanghai 18
Ashburn 16
Dublin 13
Helsinki 13
Milan 13
Dronten 8
Tehran 8
Pune 5
Zurich 5
Izmir 4
Medellín 4
Washington 4
Manchester 3
Rome 3
Seattle 3
Tokyo 3
Ankara 2
Bergamo 2
Edgware 2
Los Angeles 2
Mumbai 2
Redhill 2
Boardman 1
Brierley Hill 1
Buccinasco 1
Budapest 1
Castelseprio 1
Frankfurt am Main 1
Fremont 1
Heinrichsthal 1
Kyoto 1
Nishikicho 1
Oldbury 1
Oslo 1
Rockville 1
Sapporo 1
Secaucus 1
Senigallia 1
Sunapee 1
Vaprio d'Adda 1
Totale 320
Salva come PNG Salva come JPEG
Nome #
Magnetic Resonance Imaging Evaluation of Perivascular Space Abnormalities in Neuromyelitis Optica 36
Autologous haematopoietic stem cell transplantation with thiotepa-cyclophosphamide conditioning in aggressive multiple sclerosis: clinical experience in eight patients 31
U-Fiber Leukoencephalopathy Due to a Novel Mutation in the TACO1 Gene 21
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 20
Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. 19
Dysregulation of MS risk genes and pathways at distinct stages of disease 16
Brain and cord imaging features in neuromyelitis optica spectrum disorders 16
Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response 16
Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study 14
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis 14
Autologous haematopoietic stem cell transplantation in aggressive forms of neuromyelitis optica (NMO) and NMO spectrum disorders 14
Allogeneic haematopoietic stem cell transplantation in refractory neuromyelitis optica spectrum disorders 14
In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis 14
Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach 14
Critical role for prokineticin 2 in CNS autoimmunity 13
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 13
Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders 13
Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod 13
Efficacy and safety of nabiximols (Sativex (R)) on multiple sclerosis spasticity in a real-life Italian monocentric study 12
Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment 12
Forceps minor damage and co-occurence of depression and fatigue in multiple sclerosis 12
Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography 12
Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis 12
Breastfeeding is not related to postpartum relapses in multiple sclerosis 11
Natalizumab treatment after autologous haematopoietic stem cell transplantation in patients with aggressive multiple sclerosis 11
Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: An Italian multi-center study using the Beck Depression Inventory 11
Clinical and MRI predictors of response to interferon‐beta and glatiramer acetate in relapsing–remitting multiple sclerosis patients 10
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. 10
Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients 10
Functional brain connectivity abnormalities and cognitive deficits in neuromyelitis optica spectrum disorder 10
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. 10
Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: a case report 9
THIOTEPA-CYCLOPHOSPHAMIDE HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE FORMS OF MULTIPLE SCLEROSIS: RESULTS IN 9 PATIENTS 9
Neuromyelitis optica spectrum disorders: Long-term safety and efficacy of rituximab in Caucasian patients 9
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 9
Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. 9
Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO) 9
Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction. 9
Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis 8
Recurrence of disease activity after repeated Natalizumab withdrawals. 8
Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. 8
Mapping regional grey and white matter atrophy in relapsing-remitting multiple sclerosis. 8
Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: A post-marketing observational study 8
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: An Italian multicenter study 8
Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice 8
Concurrence of NMOSD and ALS in a patient with hexanucleotide repeat expansions of C9orf72 8
Disclosing the diagnosis of multiple sclerosis: The Profile Project 8
Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study 8
Sars-CoV2 infection in pregnant women with multiple sclerosis 7
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 7
Practice of yoga may cause damage of bothsciaticnerves: a case report 7
the multiple sclerosis knowledge Questionnaire: a self administered instrument of recently diagnosed patients 7
Multiple sclerosis progression is not associated with birth timing in Italy 7
Regional gray matter atrophy is largely unrelated to white matter tissue loss in relapsing remitting multiple sclerosis. 7
Evoked Potential Abnormalities Predict Disability Progression at 5 Years in Patients with CIS 7
Neuromyelitis optica remission after allo-SCT: results in 2 patients and correlation with T- and B-cell biomarkers of tolerance 7
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis 7
Neuromyelitis optica: Concepts in evolution 7
Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood 7
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. 7
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results 7
Mitoxantrone: benefits and risks in multiple sclerosis patients 6
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. 6
NMO spectrum disorder and optic neuritis: are VEPs useful? 6
Evoked potentials scores: a useful tool in monitoring and predicting the course of multiple sclerosis? 6
Optical coherence tomography and visual-evoked potentials: which is more sensitive in multiple sclerosis? 6
Thiotepa-cyclophosphamide high-dose immunosuppressive therapy with autologous haematopoietic stem cell transplantation in aggressive forms of multiple sclerosis: results in 9 patients 6
MGAT5 and disease severity in progressive multiple sclerosis 6
Oral corticosteroids for multiple sclerosis relapse 6
Evolving concepts in the treatment of relapsing multiple sclerosis 6
Experience of an information aid for newly diagnosed multiple sclerosis patients: A qualitative study on the SIMS-Trial 6
Prognostic value of serum neurofilaments in patients with clinically isolated syndromes 6
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 5
Signs and symptoms of COVID-19 in patients with multiple sclerosis 5
Differential diagnosis of optic neuritis in neuromyelites optica and multiple sclerosis: are VEPs useful? 5
Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression 5
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study 4
Stem Cell-Based Therapies, Remyelination, and Repair Promotion in the Treatment of Multiple Sclerosis 3
Evoked potential abnormalities predict disability progression at 5 years in patients with CIS 3
Totale 784
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.749
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.749
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 0 1
2019/20209 4 0 0 1 0 0 0 0 2 2 0 0
2020/202111 0 0 2 0 1 2 2 0 3 0 1 0
2021/202244 0 0 0 30 1 2 1 3 2 3 0 2
2022/2023504 182 129 55 2 5 60 19 15 19 6 9 3
2023/2024182 7 26 22 26 27 42 4 20 0 7 1 0
Totale 784